Objective: CORRELATION OF CLINICAL PROFILE OF PARKINSONISM WITH MOLECULAR IMAGING (TRODAT AND PET-CT BRAIN)
Background: The current study aims to establish the role of Molecular imaging (TRODAT/PET CT) in differentiation of various parkinsonian syndromes and to study the correlation of clinical profile of Parkinsonism with molecular imaging (TRODAT SPECT/PET CT).
Method: This was a cross sectional hospital based observational study in which subjects were recruited after fulfilling inclusion and exclusion criteria. Detailed clinical and neurological examination was carried out for all the 71 patients. Hoehn and Yahr staging and MDS UPDRS was done for all the cases of PD (Parkinson Disease) and PPS (Parkinson Plus Syndrome) with MMSE (Mini Mental State Examination) and detailed cognitive assessment.99mTc-TRODAT-1 SPECT/CT was performed. A standard 18F-fluorodeoxiglucose-positron emission tomography/computed tomography (FDG-PET/CT) static brain study were also performed according to requirement to differentiate amongst various parkinsonian syndromes. 9-12 months follow up done in all cases before final diagnosis was made
Results: The mean age of onset was 58.35 years. On TRODAT SPECT-CT a lower SUR could reliably differentiate PD (Parkinson Disease) patients from ET (Essential Tremors) patients with a sensitivity ranging from 84-94%. (p <0.001). Among PD patients, TRODAT uptake was asymmetrically reduced opposite to the side of onset in cases of asymmetry (p<0.001) and was also significantly associated with cognition, MMSE score and H&Y staging of the disease but it was not possible to differentiate amongst various parkinsonian plus syndromes. On further FDG-PET imaging, various parkinsonian syndromes could be differentiated by disease related patterns by a sensitivity ranging from (66%-100% and a specificity of (92-100%) (p <0.001) with the sensitivity being lowest for PDRP( Parkinson disease related Pattern) and highest for CBGDRP (Corticobasal degeneration related pattern).
Conclusion: We conclude that molecular imaging can be used as a reliable tool in differentiating different types of parkinsonian and non-parkinsonian syndromes
To cite this abstract in AMA style:
S. Lavania, A. Pattojoshi, AH. Khan. Correlation of clinical profile of Parkinsonism with molecular imaging [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/correlation-of-clinical-profile-of-parkinsonism-with-molecular-imaging/. Accessed June 15, 2025.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/correlation-of-clinical-profile-of-parkinsonism-with-molecular-imaging/